Ocular Therapeutix, Inc.
OCUL Nasdaq
SEC CIK 1393434
Follow Ocular Therapeutix
Weekly email: filings, results
Revenue, last quarter
$12.9M
−11.5% vs same quarter last year
Net income
−$94.8M
−36.5% vs same quarter last year
EPS, diluted
−$0.42
−10.5% vs same quarter last year
Operating cash flow
−$65.6M
−29.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $52M | −$265.9M |
| FY24 | $63.7M | −$193.5M |
| FY23 | $58.4M | −$80.7M |
| FY22 | $51.5M | −$71M |
| FY21 | $43.5M | −$6.6M |
| FY20 | $17.4M | −$155.6M |
| FY19 | $4.2M | −$86.4M |
| FY18 | $2M | −$60M |
| FY17 | $1.9M | −$63.4M |
| FY16 | $1.9M | −$44.7M |
| FY15 | $1.8M | −$39.7M |
| FY14 | $772K | −$28.6M |
| FY13 | - | −$13.3M |
| FY12 | $10K | −$14.1M |
| FY11 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 87.3% | −519.8% | −511.9% |
| FY24 | 91.2% | −269.6% | −303.7% |
| FY23 | 91% | −141% | −138.1% |
| FY22 | 91.2% | −152.7% | −138% |
| FY21 | 89.9% | −179.3% | −15.1% |
| FY20 | 88% | −361.1% | −894.3% |
| FY19 | 45% | −2029.9% | −2043.3% |
| FY18 | 76.6% | −2970.8% | −3014% |
| FY17 | 76.2% | −3220.1% | −3296.2% |
| FY16 | 76.5% | −2296% | −2369% |
| FY15 | 81.8% | −2182.7% | −2271.3% |
| FY14 | 88.2% | −3509.6% | −3710.9% |
| FY13 | - | - | - |
| FY12 | 30% | −136710% | −140930% |
| FY11 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$216.9M |
| FY24 | −$136M |
| FY23 | −$76.3M |
| FY22 | −$63.3M |
| FY21 | −$66.7M |
| FY20 | −$54.4M |
| FY19 | −$79.8M |
| FY18 | −$51.1M |
| FY17 | −$58.7M |
| FY16 | −$35.9M |
| FY15 | −$35.5M |
| FY14 | −$21.8M |
| FY13 | −$13M |
| FY12 | −$12.8M |
| FY11 | - |
- Ocular Therapeutix
- Healthcare median
Show the numbers
| Year | Ocular Therapeutix | Healthcare median |
|---|---|---|
| FY25 | −511.9% | −30.6% |
| FY24 | −303.7% | −47% |
| FY23 | −138.1% | −58% |
| FY22 | −138% | −80.4% |
| FY21 | −15.1% | −71.9% |
| FY20 | −894.3% | −62.2% |
| FY19 | −2043.3% | −46.3% |
| FY18 | −3014% | −49.6% |
| FY17 | −3296.2% | −45.9% |
| FY16 | −2369% | −36% |
| FY15 | −2271.3% | −38.4% |
| FY14 | −3710.9% | −35.5% |
| FY13 | - | −37.1% |
| FY12 | −140930% | −29.1% |
| FY11 | - | −27.9% |